Thyrocare Technologies Ltd

Thyrocare Technologies Ltd

472.75
INR
+16.05
(+3.51%)
55.67BMarket Cap
Nov 04Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
9.08
12.32
15.61
18.37
21.75
24.94
26.98
30.85
36.65
32.58
35.76
42.79
51.64
- -
Basic EPS, GAAP
2.86
3.05
3.35
2.67
5.79
5.32
5.58
7.14
11.1
4.06
4.46
5.75
10.24
- -
Free Cash Flow per Basic Share
1.96
1.65
3.46
3.31
3.93
3.75
9.97
5.55
4.76
5.4
6.68
9.21
12.09
- -
Dividend per Share
- -
1.28
2.45
2.51
3.33
1.68
8.33
3.33
5
5
6
5.99
9.33
- -
Book Value per Share
12.8
17.15
23.8
25.3
27.5
27.47
23.13
26.94
33.18
33.65
33.16
34.39
36.79
- -
Tangible Book Value per Share
12.74
14.24
17.09
18.63
20.77
20.62
16.73
20.55
26.81
27.28
26.57
27.28
29.76
- -
Basic Weighted Avg Shares
161
148
154
161
161
160
158
159
159
159
159
159
159
159
Sales/Revenue/Turnover
1,463
1,830
2,410
2,953
3,505
3,994
4,274
4,891
5,815
5,172
5,679
6,807
8,219
- -
Operating Margin (%)
42.71
33.62
31.46
33.6
35.95
32.07
33.14
28.86
34.71
16.36
16.33
19.95
24.9
- -
Depreciation Expense
64
129
182
181
201
262
319
303
339
387
470
553
586
- -
Net Income, GAAP
462
452
518
428
933
851
884
1,132
1,761
645
708
915
1,630
- -
Effective Tax Rate (%)
33.01
34.87
36.68
47.54
35.66
38.33
37.04
25.79
22.65
27.35
27.6
37.6
23.5
- -
Profit Margin (%)
31.55
24.71
21.5
14.51
26.62
21.32
20.68
23.14
30.29
12.47
12.46
13.44
19.84
- -
Working Capital
1,223
1,034
1,214
1,319
1,221
1,154
703
1,453
2,055
1,958
1,880
2,159
2,624
- -
LT Debt
250
- -
55
73
- -
25
82
55
157
161
227
169
392
- -
Total Equity
2,063
3,124
3,836
4,078
4,433
4,351
3,667
4,273
5,266
5,352
5,276
5,471
5,860
- -
Return on Invested Capital (%)
20.08
14.71
13.6
9.29
19.53
17.92
20.82
26.74
35.4
11.36
12.1
15.37
26.09
- -
Return on Capital (%)
22.17
17.07
14.75
10.68
21.79
19.4
21.93
27.93
36.21
12
13.3
16.5
27.37
- -
Return on Common Equity (%)
25.2
18.74
15.7
10.83
21.92
19.39
22.05
28.5
36.93
12.16
13.34
17.05
28.8
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
115
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
392
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
159
159
159
Market Capitalization
70,986
55,667
87,334

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
3,723
- -
Cash, Cash Equivalents & STI
- -
2,311
- -
Accounts Receivable, Net
- -
739
- -
Inventories
- -
485
- -
Total Current Liabilities
- -
1,099
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
115
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.82%
6.85%
7.12%
Free Cash Flow
22.48%
18.49%
31.37%
Net Income, GAAP
23.3%
21.9%
78.17%
Sales/Revenue/Turnover
13.49%
11.65%
20.74%
Total Cash Common Dividend
44.69%
25.19%
55.73%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,569
1,774
1,659
1,872
6,807
2026
1,930
- -
1,955
2,240
8,219
2027
2,400
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.52
1.66
1.15
1.39
5.75
2026
2.41
- -
1.82
2.99
10.24
2027
3.23
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
5.99
2026
- -
- -
- -
- -
9.33
2027
- -
- -
- -
- -
- -

Company Description

CEO
Rahul Franklin Guha
Full Time Employees
2,092
Sector
Health services
Industry
Medical/Nursing services
Address
D/37-3, TTC Industrial Area Navi Mumbai MA India 400703
IPO Date
May 9, 2016
Business
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, hospitals and clinics primarily in India. The company operates through diagnostic testing services, imaging services and other segments; offers more than 900 tests and 288 profiles including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility and infectious disease tests; provides preventive wellness packages under the Aarogyam brand such as Aarogyam and Jaanch; sells glucometers and glucostrips under the Sugarscan brand, consumables and radiopharmaceutical products; conducts cancer diagnosis through its Nueclear brand and water testing through Whaters; and delivers imaging services including PET-CT scans, nuclear scanning, MRI, CT scans and ultrasonography via subsidiary Nueclear Healthcare Limited and recent 51% stake in Pulse Hitech Health Services LLP. Thyrocare Technologies maintains a centralized processing laboratory and regional facilities in Navi Mumbai with air-cargo logistics supporting a franchise network exceeding 10,100 active centers nationwide and international expansion in markets like Tanzania. Founded in 1995 and incorporated in 2000, the company is headquartered in Navi Mumbai, India, and functions as a subsidiary of Docon Technologies Private Limited. Recent developments include the acquisition of Vimta Labs' diagnostic and pathological services business in 2024 to bolster presence in South India and Telangana; a 2:1 bonus issue announced in October 2025 with record date November 28, 2025; franchise-led growth with pathology volumes up 21% year-on-year and bundled packages rising 19-31%; full NABL accreditation across all laboratories; and a strategic shift in FY24 toward cost streamlining, pay-for-performance incentives and volume-led expansion driving revenue growth of 24.5% in franchise pathology.